New combination of drugs cause enhanced weight loss
Researchers at the University of Pennsylvania have found that a unique combination of weight loss drugs can have a dramatic effect on laboratory animals. The researchers studied the effect of two different drug classes that affect the hormones amylin and glucagon-like peptide-1 (GLP-1). They found that cycling between the two drug regimens over the course of a month achieved a greater degree of weight loss than normal regimens. These include a continuous combined therapy or using just one of the drugs.
Unlike many other trials that examine new drugs, this research involves drugs that are already approved by many different organisations, including the FDA. This means that the types of regimens being suggested could be in use in the very near future. Currently, the authors are finalising their work to show how the two hormonal systems interact with each other to achieve this greater weight loss.